Oppenheimer & Co’s Pliant Therapeutics PLRX Stock Holding History

Oppenheimer & Co’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,877	Closed	-$197K	–	1496
2023 Q4	$197K	Sell	10,877 -1,258	-10%	-$19.1K	﹤0.01%	1288
2023 Q3	$210K	Buy	+12,135	New	+$210K	﹤0.01%	1250
2023 Q2	–	Sell	-7,667	Closed	-$204K	–	1465
2023 Q1	$204K	Buy	+7,667	New	+$218K	﹤0.01%	1262

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Oppenheimer & Co's PLRX Position: Q1 2024 in Review

Oppenheimer & Co sold out of Pliant Therapeutics (PLRX) in Q1 2024, closing a stake of 10,877 shares — an estimated $197K sold.

Oppenheimer & Co first reported a position in PLRX in Q1 2023 and held it in 3 quarters. The position peaked at $210K in Q3 2023. 135 funds tracked by Wall St. Rank hold PLRX as of Q1 2024.

Oppenheimer & Co reported no remaining Pliant Therapeutics position as of Q1 2024 after selling out during the quarter.
Oppenheimer & Co sold 10,877 Pliant Therapeutics shares in Q1 2024, an estimated $197K.
Oppenheimer & Co first reported a position in Pliant Therapeutics in Q1 2023 and held it in 3 quarters.
Oppenheimer & Co's Pliant Therapeutics position peaked at $210K in Q3 2023.
135 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2024.

Based on Oppenheimer & Co's 13F filing for Q1 2024, filed 7 May 2024.